Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study

British Journal of Haematology

Volumn 102, Issue 3, 1998, Pages 783-790

  Van Zaanen, H C T ^a,e   Lokhorst, H M ^b   Aarden, L A ^c   Rensink, H J A M ^c   Warnaar, S O ^d   Van Der Lelie, J ^a   Van Oers, M H J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d Centocor   (Netherlands)

^e SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Anti interleukin 6; Chimaeric; Multiple myeloma

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BIOACCUMULATION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOGENICITY; MALE; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA;

AGED; AGRANULOCYTOSIS; ANTIBODIES, MONOCLONAL; BETA 2-MICROGLOBULIN; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HALF-LIFE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MUSCLE PROTEINS; MYELOMA PROTEINS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031811798     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00835.x     Document Type: Article

References (43)

1. Aarden, L. (1991) Plasmacytomas. Mechanisms of B-cell Neoplasm (ed. by F. Melchens and M. Potter), pp. 419-43. Editione Roche, Basel.
2. Aarden, L., De Groot, E., Schaap, O. & Lansdorp, P. (1987) Production of hybridoma growth factor by human monocytes. European Journal of Immunology, 17, 1411-1416.
3. Anderson, K., Jones, R., Morimoto, C., Leavitt, P. & Barut, B. (1989) Response patterns of purified myeloma cells to hematopoietic growth factors. Blood, 73, 1915-1924.
4. Asano, S., Okano, A., Ozawa, K., Nakahota, T., Ishibashi, T., Koike, K., Kimura, H., Tanioko, Y., Hirano, T., Kishimoto, T., Takahu, F. & Akiyoma, Y. (1990) In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood, 75, 1602-1605.
5. Asaoku, H., Kawano, M., Iwato, K., Tanabe, O., Tanaka, T., Hirano, T., Kishimoto, T. & Kuramoto, A. (1988) Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. Blood, 72, 429-432.
6. Barille, S., Colette, M., Bataille, R. & Amiot, M. (1995) Myeloma cells upregulate IL6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood, 86, 3151-3159.
7. Bataille, R., Barlogie, B., Lu, Z., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., & Klein, B. (1995) Biologic effects of anti-interleukin 6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685-691.
8. Bataille, R., Chappard, D. & Klein, B. (1992) Mechanism of bone lesions. In: 'Multiple myeloma'. Hematology/Oncology Clinics of North America, 6, 285-295.
9. Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. (1989) Serum levels of IL6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
10. Brakenhoff, J., Hart, M., De Groot, E., Di Padova, F. & Aarden, L. (1990) Structure-function analysis of human IL6: epitope mapping of neutralizing monoclonal antibodies with amino-and carboxyl-terminal deletion mutants. Journal of Immunology, 145, 561-568.
11. Durie, B. & Salmon, S. (1975) A clinical staging system for multiple myeloma. Cancer, 36, 842-854.
12. Ehlers, M., Grotzinger, J., de Hon, F., Mullberg, J., Brakenhoff, J., Liu, J., Wollmer, A. & Rose-John, S. (1994) Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. Journal of Immunology, 153, 1744-1751.
13. Foerster, J. (1993) Multiple myeloma. Wintrobe's Clinical Hematology, 9th edn (ed. by G. Lee, Th. Bithell, J. Foerster, J. Athens and J. Lukens), p. 2222. Lea and Febiger, Philadelphia.
14. Heinrich, P., Castell, J. & Andus, T. (1990) Interleukin-6 and the acute phase response. Biochemical Journal, 265, 621-636.
15. Heremans, H., Dillen, C., Put, W., Van Damme, J. & Billiau, A. (1992) Protective effect of anti-IL6 antibody against endotoxin, associated with paradoxically increased IL6 levels. European Journal of Immunology, 22, 2395-2401.
16. Hilbert, D, Kopf, M., Mock, B., Kohler, G. & Rudikoff, S. (1995) Interleukin 6 is essential for in vivo development of B lineage neoplasms. Journal of Experimental Medicine, 182, 243-248.
17. Hoffman, T. (1990) Anticipating, recognizing and preventing hazards associated with in vivo use of monoclonal antibodies: special considerations related to human anti-mouse antibodies. Cancer Research, 50, 1049S-1050s.
18. Joshua, D., Petersen, A., Brown, R., Pope, B., Snowden, L. & Gibson, J. (1996) The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. British Journal of Haematology, 94, 76-81, 1996.
19. Juge-Morinea, N., Francois, S., Puthier, D., Godard, A., Bataille, R. & Amiot, M. (1995) The gp1 30 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells. British Journal of Haematology, 90, 707-710.
20. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanaka, H., Kuramoto, A. & Kishimoto, T. (1988) Autocrine generation and requirement of BSF 2/IL6 for human multiple myelomas. Nature, 332, 83-85.
21. Kawano, M., Huang, N., Harada, H., Harada, Y., Sakai, A., Tanaka, H., Iwato, K. & Kuramoto, A. (1993) Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood, 82, 564-570.
22. Kishimoto, T. (1989) The biology of interleukin-6. Blood, 74, 1-10.
23. Klein, B., Wijdenes, J., Zhang, X.G., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clement, C., Morel-Fournier, B., Lu, Z., Mannoni, P., Sany, J. & Bataille, R. (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78, 1198-1204.
24. Klein, B., Zhang, X.G., Jourdan, M., Boiron, J., Portier, M., Lu, Z., Wijdenes, J., Brochier, J. & Bataille, R. (1990) IL6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. European Cytokine Network, 1, 193-201.
25. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, J., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by IL6. Blood, 73, 517-526.
26. Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y. & Roodman, G. (1990) IL6 stimulates osteoclast-like multinucleated cell formation in long-term human marrow cultures by inducing IL-1 release. Journal of Immunology, 144, 4226-4230.
27. Libert, C., Takahashi, N., Cauwels, A., Brouckaert, P., Bluethmann, H. & Fiers. W. (1994) Response of IL-6 deficient mice to TNF-induced metabolic changes and lethality. European Journal of Immunology, 24, 2237-2242.
28. Lokhorst, H., Lamme, M., de Smet, M., Klein, M., de Weger, R., van Oers, R. & Bloem, A. (1994) Primary tumor cells of myeloma patients induce IL6 secretion in long-term bone marrow cultures. Blood, 84, 2269-2277.
29. Martens, E., Dillen, C., Put, W., Heremans, H., Van Damme, J. & Billiau. A. (1993) Increased circulating interleukin 6 activity in endotoxin-challenged mice pretreated with anti-IL6 antibody is due to IL6 accumulated in antigen-antibody complexes. European Journal of Immunology, 23, 2026-2029.
30. May, L., Neta, R., Moldawer, L., Kenney, J., Patel, K. & Sehgal, P. (1993) Antibodies chaperone circulating IL-6: paradoxical effects of anti-IL6 'neutralizing' antibodies in vivo. Journal of Immunology, 151, 3225-3236.
31. May, L., Patel, K., Garcia, D., Ndubuisi, M., Ferrone, S., Mittelman, A., Mackiewicz, A. & Sehgal, P. (1994) Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood, 84, 1887-1895.
32. Mihara, M., Koishihara, Y., Fukui, H., Yasukawa, K. & Ohsugi, Y. (1991) Murine anti-human IL6 monoclonal antibody prolongs the half-life time in circulating blood and thus prolongs the bioactivity of human IL6 in mice. Immunology, 74, 55-59.
33. Montero-Julian, F., Klein, B., Gautherot, E. & Brailly, H. (1995) Pharmacokinetic study of IL6 therapy with monoclonal antibodies: enhancement of IL6 clearance by cocktails of anti-IL6 antibodies. Blood, 85, 917-924.
34. Nordan, R., Pumphrey, J. & Rudikoff, S. (1987) Purification and NH2-terminal sequence of a plasmacyloma growth-factor derived from the murine macrophage cell line P 388 D1. Journal of Immunology, 139, 813-817.
35. Roodman, G. (1995) Osteoclast function in Paget's disease and multiple myeloma. Bone, 17, 57-61S.
36. Sonneveld, P., Schoester, M. & de Leeuw, K. (1991) In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors. British Journal of Haematology, 79, 589-594.
37. Stahl, C., Zucker-Kranklin, D., Evatt, B. & Winton, E. (1991) Effects of human Interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates. Blood, 78, 1467-1475.
38. Stouthard, J., Goey, H., de Vries, E., de Mulder, P., Groenewegen, A., Pronk, L., Stoter, G., Sauerwein, H., Bakker, P. & Veenhof, C. (1996) Recombinant human interleukin-6 in metastatic renal cell cancer: a phase II trial. British Journal of Cancer, 73, 789-793.
39. Van Oers, M., van Zaanen, H. & Lokhorst, H. (1993) Interleukin-6, a new target for therapy in multiple myeloma? Annals of Hematology, 66, 219-223.
40. Van Zaanen, H., Koopmans, R., Aarden, L. Rensink, H., Stouthard, J., Warnaar, S., Lokhorst, H. & van Oers, M. (1996) Endogenous IL-6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed back loop. Journal of Clinical Investigation, 98, 1441-1448.
41. Wickenhauser, C., Lorenzen, J., Thiele, J., Hillienhof, A., Jungheim, K., Schmitz, B., Hansmann, M. & Fischer, R. (1995) Secretion of cytokines (IL-1alpha, IL-3, IL-6 and GM-CSF) by normal human bone marrow megakaryocytes. Blood, 85, 685-691.
42. Zhang, X.G., Bataille, R., Wijdenes, J. & Klein, B. (1992) Interleukin 6 dependence of advanced malignant plasma cell dyscrasias. Cancer, 69, 1373-1376.
43. Zhang, X.G., Klein, B. & Bataille, R. (1989) IL6 is a potent myeloma cell growth factor in patients with aggressive MM. Blood, 74, 11-13.